Literature DB >> 28101987

Delivery Outcomes of Patients with Acute Migraine in Pregnancy: A Retrospective Study.

Tracy B Grossman1, Matthew S Robbins2, Shravya Govindappagari3, Ashlesha K Dayal3.   

Abstract

OBJECTIVE: To describe labor and delivery outcomes in pregnant patients presenting to the hospital setting with an acute severe migraine headache attack earlier in the same gestation.
METHODS: We retrospectively reviewed pregnancy and delivery records from a database of consecutive inpatient neurology consultations for acute headache in pregnant women over a 5 year period.
RESULTS: We identified 86 pregnant women with acute migraine. The mean age was 29.3 (±6.4) years. Nearly half had migraine with aura (35/86 [40.7%]), 12.8% (12/86) had chronic migraine, and 31.4% (27/86) presented in status migrainosus. Complication rates included 54.7%([41/75], 95% CI 29.87, 52.13) for at least one adverse outcome, 28.0% ([21/75], 95% CI 11.78, 30.22) for preterm delivery, 21.3% ([16/75], 95% CI 7.7, 24.3) for preeclampsia, 30.6% ([23/75] 95% CI 13.48, 32.52) for cesarean delivery, and 18.7% ([14/75] 95% CI 6.15, 21.85) for low birthweight.
CONCLUSIONS: Pregnant women seeking treatment for acute migraine headache experienced a higher rate of preterm delivery, preeclampsia, and low birthweight but a lower rate of cesarean delivery than the local and general populations. More than half (54.7% [41/75] 95% CI 29.87, 52.13) of the study patients experienced some type of adverse birth outcome, suggesting that pregnancies in migraine patients presenting to an acute care setting may benefit from more intense surveillance.
© 2017 American Headache Society.

Entities:  

Keywords:  birth outcome; migraine; pregnancy

Mesh:

Year:  2017        PMID: 28101987     DOI: 10.1111/head.13023

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  9 in total

Review 1.  Women and Migraine: the Role of Hormones.

Authors:  Candice Todd; Ana Marissa Lagman-Bartolome; Christine Lay
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-31       Impact factor: 5.081

Review 2.  Neurology of Preeclampsia and Related Disorders: an Update in Neuro-obstetrics.

Authors:  Eliza C Miller; Sarah Vollbracht
Journal:  Curr Pain Headache Rep       Date:  2021-04-07

Review 3.  Secondary Headaches During Pregnancy: When to Worry.

Authors:  Claire H Sandoe; Christine Lay
Journal:  Curr Neurol Neurosci Rep       Date:  2019-04-22       Impact factor: 5.081

4.  Pre-, Peri-, and Neonatal Factors Associated with Autism Spectrum Disorder: Results of a Lebanese Case-control Study.

Authors:  Aline Hajj; Souheil Hallit; Rouba El-Khatib; Sandra Abi Haidar; Fabienne Hajj Moussa Lteif; Layal Hajj; Maguy Moudawar; Lydia Rabbaa Khabbaz
Journal:  Innov Clin Neurosci       Date:  2022 Jul-Sep

5.  Population-Based Study of Nonelective Postpartum Readmissions in Women With Stroke, Migraine, Multiple Sclerosis, and Myasthenia Gravis.

Authors:  Barbara M Decker; Dylan Thibault; Kathryn A Davis; Allison W Willis
Journal:  Neurology       Date:  2022-02-15       Impact factor: 11.800

6.  Pregestational neurological disorders among women of childbearing age-Nationwide data from a 13-year period in Hungary.

Authors:  Dániel Bereczki; Mónika Bálint; András Ajtay; Ferenc Oberfrank; Ildikó Vastagh
Journal:  PLoS One       Date:  2022-09-21       Impact factor: 3.752

Review 7.  Headache and pregnancy: a systematic review.

Authors:  A Negro; Z Delaruelle; T A Ivanova; S Khan; R Ornello; B Raffaelli; A Terrin; U Reuter; D D Mitsikostas
Journal:  J Headache Pain       Date:  2017-10-19       Impact factor: 7.277

Review 8.  The Potential Protective Role of Aspirin Against Migraine in Pregnant Women.

Authors:  Xijing Liu; Yunhui Gong
Journal:  Med Sci Monit       Date:  2020-08-02

9.  Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes.

Authors:  Anick Bérard; Shannon Strom; Jin-Ping Zhao; Shashi Kori; Detlef Albrecht
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.